Дарья Карташева-Эберц открыла доступ к своему вебинару "Иммунная система"
Кроме прочих, у этого вебинара есть одно крутое преимущество - он подходит и врачам, и пациентам.
Так что я очень рекомендую для всех коллег, кто хочет восполнить пробелы в базовых знаниях, и для пациентов, у которых фраза "поднять иммунитет" существует в обиходе.
https://docma.ru/immunology
Там сегодня скидка😎
BY Infodoc
That growth environment will include rising inflation and interest rates. Those upward shifts naturally accompany healthy growth periods as the demand for resources, products and services rise. Importantly, the Federal Reserve has laid out the rationale for not interfering with that natural growth transition.It's not exactly a fad, but there is a widespread willingness to pay up for a growth story. Classic fundamental analysis takes a back seat. Even negative earnings are ignored. In fact, positive earnings seem to be a limiting measure, producing the question, "Is that all you've got?" The preference is a vision of untold riches when the exciting story plays out as expected.
At a time when the Indian stock market is peaking and has rallied immensely compared to global markets, there are companies that have not performed in the last 10 years. These are definitely a minor portion of the market considering there are hundreds of stocks that have turned multibagger since 2020. What went wrong with these stocks? Reasons vary from corporate governance, sectoral weakness, company specific and so on. But the more important question is, are these stocks worth buying?
Infodoc from vn